Bristol Myers Squibb & Co. (NYSE:BMY) on Friday announced topline results from the Phase 3 INDEPENDENCE trial evaluating ...

Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same ...

Bristol Myers Squibb said on Friday its blockbuster drug Reblozyl in combination with another therapy failed to meet the main ...

The company’s AI approach allows molecule candidates to be vetted for efficacy and other properties early in development.

Sotyktu (deucravacitinib) has been assigned a Prescription Drug User Fee Act (PDUFA) goal date of March 6, 2026.

The Subject Expert Committee (SEC) under the Cardiovascular division of the Central Drugs Standard Control Organisation (CDSCO) has approved the protocol amendment submitted ...

Bristol Myers (BMY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Shares of Bristol Myers Squibb Co. BMY advanced 2.00% to $48.98 Wednesday, on what proved to be an all-around favorable trading session for the stock market, with the S&P 500 Index SPX rising 0.78% to ...

Bristol-Myers Squibb recently wrapped up a pivotal study in Japan, focusing on the quality of life in patients with ...

Bristol Myers (BMY) delivered an impressive performance in the past month after being under pressure for quite some time. The stock regained some of its lost ground and added 6.3% in a month compared ...

Bristol-Myers Squibb’s shares (currently trading at $46.80) have posted a disappointing 18% loss, well below the S&P 500’s ...